GENF
NEUTRALGenflow Biosciences Partners with AI Firm Heureka Labs to Enhance Gene Therapy Research
The biotechnology company has signed an agreement with an AI firm to boost its gene therapy research capabilities.
Genflow Biosciences
1.0500GBX
-4.55%
Market Cap
4.11M
Volume
332.85k
18% of avg
P/E Ratio
EPS (TTM)
Beta
2.39
Day Range
1.0500p - 1.0699p
52 Week Range
0.9560p1.0500p3.4060p
1.0500p
GENF
NEUTRALGenflow Biosciences Launches New Ophthalmology Development Program
The biotechnology company is launching a new ophthalmology development program, leveraging its proprietary Centenarian SIRT6 technology to target ocular diseases.
GENF
NEUTRALGenflow Biosciences Director Increases Stake
The biotechnology company has announced a director has increased their shareholding in the business.
GENF
NEUTRALGenflow Biosciences CEO Increases Stake
The CEO of the biotechnology company has purchased additional shares in the open market.
GENF
GOODGenflow Biosciences Secures £434,083 Investment, Launches Dog Gene Therapy Trial
The biotechnology company has secured a £434,083 investment and plans to launch a clinical trial in aged dogs for its gene therapy.
GENF
GOODGenflow Biosciences Advances SIRT6 Variant Patent Application
The biotechnology company announced progress in securing patent protection for its SIRT6 variant technology, a key component of its longevity-focused pipeline.
GENF
NEUTRALDirector Increases Stake in Genflow Biosciences
Biotechnology company Genflow Biosciences sees director increase stake
GENF
NEUTRALGenflow Biosciences Announces Change in Shareholding
The biotechnology company announces a change in shareholding, with a major investor crossing below the 5% threshold.
GENF
GOODGenflow Biosciences Advances Aging Therapies in 2024
The biotechnology company reports significant advancements in its aging-related therapies, including progress on its lead compound and new initiatives in 2024.
GENF
GOODGenflow Secures €4 Million in Non-Dilutive Funding for GF-1002 Development
The biotechnology company has secured €4 million in non-dilutive financial support from the Wallonia region to advance the development of its lead gene therapy, GF-1002, for the treatment of a severe liver disease.